Filana Therapeutics, Inc. (FLNA)
Healthcare
Biotechnology
1.00 $
+2.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Filana Therapeutics, Inc. (FLNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -3.9 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|
| -18 | -61 | -11 | -4.9 | -6.2 | -9.7 | -8.9 | -3.9 | -29 | |
| 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.4 | 0.2 | 0.3 | 1.0 | |
| 5.6 | 5.7 | 5.2 | 4.6 | 4.4 | 5.4 | 4.1 | 4.1 | 18 | |
| 3.8 | -40 | 6.6 | 34 | 0.1 | -3.0 | -2.9 | 0.4 | -5.3 | |
| 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.5 | 0.0 | 0.0 | 0.6 | |
| 0.0 | -0.1 | – | – | -0.1 | -0.5 | – | 0.0 | – | |
| – | 0.9 | 0.1 | 0.0 | 0.0 | -0.3 | -0.1 | 0.0 | -0.4 | |
| -18 | -60 | -11 | -4.9 | -6.3 | -11 | -8.9 | -3.9 | -30 | |
| -18 | -61 | -11 | -4.9 | -6.3 | -10 | -8.9 | -3.9 | -29 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.